New cancer clinical trial: Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy
Published on: November 15, 2017 at 10:00AM
Condition: Breast Cancer
Interventions: Biological: Leucostim 5µg/kg/day; Biological: Neupogen 5µg/kg/day
Sponsor: Dong-A ST Co., Ltd.
Recruiting
http://ift.tt/2A7msSq
More Stories
‘My 401k Misses You’: Black Woman Pumped To Meet Donald Trump In Philadelphia – July 18, 2023 at 04:56PM
Energy Provider Warns of Impending ‘Crisis,’ ‘Blackout Conditions’ Driven By Biden Plans – July 18, 2023 at 04:20PM
Dog starts barking at cows crossing a bridge, so the cows stop to have a look. – July 17, 2023 at 02:27PM